Johnson & Johnson (JNJ) earnings Q3 2026
Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of its immune disease…
Novo Nordisk CEO on rebuilding investor trust after backlash
Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in…
Meet Ottava, J&J’s surgical robot leading the healthcare giant into a lucrative new market
Johnson & Johnson is diving head-first into the deep end of the competitive robotic surgery market. The payoff…
This medical device stock looks like a gift for patient investors
Insulet is a high-quality compounder where a temporary execution issue is masking strong underlying fundamentals. Type 2 diabetes…
We’re increasing our Eli Lilly price target after another beat-and-raise quarter
Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company’s portfolio of…
This GLP-1 stock has bigger opportunities to boost its share price
Instead of betting on which single pharmaceutical company wins a drug race, West Pharmaceutical Services benefits as the…
J&J gets a big win on its new robotic surgical system — plus, a flood of earnings
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
UPS to invest $48 million in cold facilities amid GLP-1 boom
United Parcel Service (UPS) trucks are parked at a UPS drop yard on Oct. 28, 2025 in Vernon,…
The money to AI stocks is a problem, and how it can be fixed
We do not have enough money coming into this market. The funds flow only to stocks tied to…